Astria Therapeutics Inc

Company Profile

Astria Therapeutics Inc had its IPO on 2015-06-25 under the ticker symbol ATXS.

The company operates in the Healthcare sector and Biotechnology industry. Astria Therapeutics Inc has a staff strength of 45 employees.

Stock update

Shares of Astria Therapeutics Inc opened at $8.58 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $8.43 - $8.6, and closed at $8.53.

This is a -0.81% slip from the previous day's closing price.

A total volume of 51,710 shares were traded at the close of the day’s session.

In the last one week, shares of Astria Therapeutics Inc have slipped by -4.26%.

Astria Therapeutics Inc's Key Ratios

Astria Therapeutics Inc has a market cap of $335.75 million, indicating a price to book ratio of 11.3959 and a price to sales ratio of 0.

In the last 12-months Astria Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32380000. The EBITDA ratio measures Astria Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Astria Therapeutics Inc’s operating margin was 0% while its return on assets stood at -19.38% with a return of equity of -29.72%.

In Q1, Astria Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Astria Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.95 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Astria Therapeutics Inc’s profitability.

Astria Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.4614. Its price to sales ratio in the trailing 12-months stood at 0.

Astria Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$218.24 million

Total Liabilities

$6.67 million

Operating Cash Flow

$194.99 million

Capital Expenditure

$5000

Dividend Payout Ratio

0%

Astria Therapeutics Inc ended 2024 with $218.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $218.24 million while shareholder equity stood at $211.36 million.

Astria Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $6.67 million in other current liabilities, 28000.00 in common stock, $-518831000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $202.30 million and cash and short-term investments were $213.33 million. The company’s total short-term debt was $587,000 while long-term debt stood at $0.

Astria Therapeutics Inc’s total current assets stands at $215.45 million while long-term investments were $0 and short-term investments were $11.03 million. Its net receivables were $0 compared to accounts payable of $930000.00 and inventory worth $0.

In 2024, Astria Therapeutics Inc's operating cash flow was $194.99 million while its capital expenditure stood at $5000.

Comparatively, Astria Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$8.53

52-Week High

$16.28

52-Week Low

$2.36

Analyst Target Price

$24.43

Astria Therapeutics Inc stock is currently trading at $8.53 per share. It touched a 52-week high of $16.28 and a 52-week low of $16.28. Analysts tracking the stock have a 12-month average target price of $24.43.

Its 50-day moving average was $8.72 and 200-day moving average was $11.46 The short ratio stood at 3.54 indicating a short percent outstanding of 0%.

Around 95.5% of the company’s stock are held by insiders while 8171% are held by institutions.